Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
CNS Drugs
Erschienen in: CNS Drugs 2/2018

01.02.2018 | Review Article

Depression in Multiple Sclerosis: Epidemiology, Aetiology, Diagnosis and Treatment

verfasst von: Claudio Solaro, Giulia Gamberini, Fabio Giuseppe Masuccio

Erschienen in: CNS Drugs | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Depressive disorders are common in patients with multiple sclerosis, influencing their quality of life and adherence to treatments, as well as becoming more frequent with the progression of the disease and in the secondary progressive form of multiple sclerosis. Patients with multiple sclerosis often experience a typical cluster of symptoms in association with depression, such as fatigue, pain and cognitive impairment. However, the pathogenesis of multiple sclerosis-related depression remains partially unclear, even though genetic, immune-inflammatory and psychosocial factors might be seen to play a role, in addition to the brain structural alterations documented by magnetic resonance imaging studies. The high incidence and burden of depression in people affected with multiple sclerosis are matters of crucial importance. Despite such importance, the efficacy of pharmacologic treatments has been poorly studied and, for the most part, the access to non-pharmacological treatments is partially dependent on the local health system availability. It has been determined that interferon-beta and glatiramer acetate do not cause depressive symptoms; however, no definitive data in this regard are avaible for the newer disease-modifyng medications. In this review, we discuss the diagnosis, prevalence, pathogenesis, clinical aspects, magnetic resonance imaging findings and treatments available in patients experiencing multiple sclerosis-related depression.
Literatur
1.
Feinstein A, Magalhaes S, Richard JF, Audet B, Moore C. The link between multiple sclerosis and depression. Nat Rev Neurol. 2014;10:507–17.CrossRefPubMed
2.
Karatepe G, Kaya T, Günaydn R, Demirhan A, Ce P, Gedizlioğlu M. Quality of life in patients with multiple sclerosis: the impact of depression, fatigue, and disability. Int J Rehabil Res. 2011;34(4):290–8.CrossRef
3.
4.
Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol. 1997;54(5):531–3.CrossRefPubMed
5.
Tarrants M, Oleen-Burkey M, Castelli-Haley J, Lage MJ. The impact of comorbid depression on adherence to therapy for multiple sclerosis. Mult Scler Int. 2011;2011:271321.PubMedCentralPubMed
6.
Mohr DC, Goodkin DE, Islar J, Hauser SL, Genain CP. Treatment of depression is associated with suppression of nonspecific and antigen-specific th1 responses in multiple sclerosis. Arch Neurol. 2001;58:1081–6.CrossRefPubMed
7.
Patten SB, Metz LM. Depression in multiple sclerosis. Psychother Psychosom. 1997;66:286–92.CrossRefPubMed
8.
Patten SB, Beck CA, Williams JV, Barbui C, Metz LM. Major depression in multiple sclerosis: a population-based perspective. Neurology. 2003;61(11):1524–7.CrossRefPubMed
9.
Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–71.CrossRefPubMed
10.
Beck AT, Steer RA, Brown GK. BDI-II: Beck Depression Inventory manual. 2nd ed. San Antonio: Psychological Corporation; 1996.
11.
Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-Fast Screen for Medical Patients. San Antonio, TX: Psychological Corporation; 2000.
12.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.CrossRefPubMed
13.
Radloff LS. The CES-D scale a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385–401.CrossRef
14.
15.
Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41:1284–92.CrossRefPubMed
16.
Parloff MB, Kelman HC, Frank JD. Comfort, effectiveness, and self-awareness as criteria for improvement in psychotherapy. Am J Psychiatry. 1954;3:343–51.CrossRef
17.
Williams JBW, Kobak KA. Development and reliability of a structured interview guide for the Montgomery-Åsberg Depression Rating Scale (SIGMA). Br J Psychiatry. 2008;192(1):52–8.CrossRefPubMed
18.
19.
Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med. 1996;26:477–86.CrossRefPubMed
20.
Henry JD, Crawford JR. The short-form version of the Depression Anxiety Stress Scales (DASS-21): construct validity and normative data in a large non-clinical sample. J Clin Psychol. 2005;44:227–39.CrossRef
21.
Minden SL, Feinstein A, Kalb RC, Miller D, Mohr DC, Patten SB, et al. Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82:174–81.CrossRefPubMedCentralPubMed
22.
Hasselmann H, Bellmann-Strobl J, Ricken R, Oberwahrenbrock T, Rose M, Otte C, et al. Characterizing the phenotype of multiple sclerosis-associated depression in comparison with idiopathic major depression. Mult Scler. 2016;22:1476–84.CrossRefPubMed
23.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Text revision. Washington, DC: American Psychiatric Association; 2000.
24.
First MB, Spitzer RL, Gibbon M, Williams, Janet BW. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington, DC: American Psychiatric Press, Inc.; 1996.
25.
Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, et al. The Composite International Diagnostic Interview: an epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry. 1988;45(12):1069–77.CrossRefPubMed
26.
World Health Organization. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. Geneva: World Health Organization; 1993.
27.
Kessler RC, Andrews G, Mroczek D, Ustun B, Wittchen H. The World Health Organization Composite International Diagnostic Interview short-form (CIDI-SF). Int J Method Psychiatr Res. 1998;7(4):171–85.CrossRef
28.
Patten SB, Burton JM, Fiest KM, Wiebe S, Bulloch AGM, Koch M, et al. Validity of four screening scales for major depression in MS. Mult Scler J. 2015;21(8):1064–71.CrossRef
29.
Fisk JD, Morehouse SA, Brown MG, Skedgel C, Murray TJ. Hospital-based psychiatric service utilization and morbidity in multiple sclerosis. Can J Neurol Sci. 1998;25:230–5.CrossRefPubMed
30.
Pandya R, Metz L, Patten SB. Predictive value of the CES-D in detecting depression among candidates for disease-modifying multiple sclerosis treatment. Psychosomatics. 2005;46(2):131–4.
31.
Solaro C, Trabucco E, Signori A, Martinelli V, Radaelli M, Centonze D, et al. Depressive symptoms correlate with disability and disease course in multiple sclerosis patients: an Italian multi-center study using the Beck Depression Inventory. PLoS One. 2016;11(9):e0160261.CrossRefPubMedCentralPubMed
32.
Zabad RK, Patten SB, Metz LM. The association of depression with disease course in multiple sclerosis. Neurology. 2005;64:359–60.CrossRefPubMed
33.
Chwastiak L, Ehde DM, Gibbons LE, Sullivan M, Bowen JD, Kraft GH. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. J Psychiatry. 2002;159:1862–8.
34.
Koch MW, Patten S, Berzins S, Zhornitsky S, Greenfield J, Wall W, et al. Depression in multiple sclerosis: a long-term longitudinal study. Mult Scler. 2015;21:76–82.CrossRefPubMed
35.
Jonsson A, Dock J, Ravnborg MH. Quality of life as a measure of rehabilitation outcome in patients with multiple sclerosis. Acta Neurol Scand. 1996;93(4):229–35.CrossRefPubMed
36.
Smith SJ, Young CA. The role of affect on the perception of disability in multiple sclerosis. Clin Rehabil. 2000;14(1):50–4.CrossRefPubMed
37.
Avasarala JR, Cross AH, Trinkaus K. Comparative assessment of Yale Single Question and Beck Depression Inventory Scale in screening for depression in multiple sclerosis. Mult Scler. 2003;9(3):307–10.CrossRefPubMed
38.
Patti F, Cacopardo M, Palermo F, Ciancio MR, Lopes R, Restivo D, Reggio A. Health-related quality of life and depression in a Italian sample of multiple sclerosis patients. J Neurol Sci. 2003;21181(2):55–62.CrossRef
39.
McGuigan C, Hutchinson M. Unrecognised symptoms of depression in a community-based population with multiple sclerosis. J Neurol. 2006;253(2):219–23.CrossRefPubMed
40.
Gottberg K, Einarsson U, Fredrikson S, von Koch L, Holmqvist LW. A population-based study of depressive symptoms in multiple sclerosis in Stockholm county: association with functioning and sense of coherence. J Neurol Neurosurg Psychiatry. 2007;78:60–5.CrossRefPubMed
41.
Tanriverdi D, Okanli A, Sezgin S, Ekinci M. Quality of life in patients with multiple sclerosis in Turkey: relationship to depression and fatigue. J Neurosci Nurs. 2010;42(5):267–73.CrossRefPubMed
42.
Mattioli F, Bellomi F, Stampatori C, Parrinello G, Capra R. Depression, disability and cognitive impairment in multiple sclerosis: a cross sectional Italian study. Neurol Sci. 2011;32(5):825–32.CrossRefPubMed
43.
Ghajarzadeh M, Saharian MA, Daneshmand A. Fatigue, depression and sleep disturbances in Iranian patients with multiple sclerosis. Acta Medica Iranica. 2012;50(4):244–9.PubMed
44.
Kargarfard M, Eetemadifar M, Mehrabi M, Maghzi AH, Hayatbakhsh MR. Fatigue, depression, and health-related quality of life in patients with multiple sclerosis in Isfahan, Iran. Eur J Neurol. 2012;19(3):431–7.CrossRefPubMed
45.
Sundgren M, Maurex L, Wahlin A, Piehl F, Brismar T. Cognitive impairment has a strong relation to nonsomatic symptoms of depression in relapsing-remitting multiple sclerosis. Arch Clin Neuropsychol. 2013;28:144–55.CrossRefPubMed
46.
Seyed Saadat SM, Hosseininezhad M, Bakhshayesh B, Seyed Saadat SN, Nabizadeh SP. Prevalence and predictors of depression in Iranian patients with multiple sclerosis: a population-based study. Neurol Sci. 2014;35(5):735–40.CrossRefPubMed
47.
Hakim EA, Bakheit AM, Bryant TN, Roberts MW, McIntosh-Michaelis SA, Spackman AJ, et al. The social impact of multiple sclerosis: a study of 305 patients and their relatives. Disabil Rehabil. 2000;22(6):288–93.CrossRefPubMed
48.
Dahl OP, Stordal E, Lydersen S, Midgard R. Anxiety and depression in multiple sclerosis: a comparative population-based study in Nord-Trondelag County, Norway. Mult Scler. 2009;15(12):1495–501.CrossRefPubMed
49.
Poder K, Ghatavi K, Fisk JD, Campbell TL, Kisely S, Sarty I, Stadnyk K, Bhan V. Social anxiety in a multiple sclerosis clinic population. Mult Scler. 2009;15(3):393–8.CrossRefPubMed
50.
da Silva AM, Vilhena E, Lopes A, Santos E, Goncalves MA, Pinto C, Moreira I, Mendonca D, Cavaco S. Depression and anxiety in a Portuguese MS population: associations with physical disability and severity of disease. J Neurol Sci. 2011;306(1–2):66–70.CrossRefPubMed
51.
Wood B, Van der Mei IA, Ponsonby AL, Pittas F, Quinn S, Dwyer T, et al. Prevalence and concurrence of anxiety, depression and fatigue over time in multiple sclerosis. Mult Scler. 2013;19(2):217–24.CrossRefPubMed
52.
Ferrando SJ, Samton J, Mor N, Nicora S, Findler M, Apatoff B. Patient Health Questionnaire-9 to screen for depression in outpatients with multiple sclerosis. J MS Care. 2007;9:99–103.CrossRef
53.
Patten SB, Metz LM, Reimer MA. Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population. Mult Scler. 2000;6(2):115–20.CrossRefPubMed
54.
Marrie RA, Fisk JD, Stadnyk KJ, Yu BN, Tremlett H, Wolfson C, Warren S, Bhan V. The incidence and prevalence of multiple sclerosis in Nova Scotia, Canada. Can J Neurol Sci. 2013;40(6):824–31.CrossRefPubMed
55.
Mohr DC, Hart SL, Julian L, Tasch ES. Screening for depression among patients with multiple sclerosis: two questions may be enough. Mult Scler. 2007;13(2):215–9.CrossRefPubMed
56.
Espinola-Nadurille M, Colin-Piana R, Ramirez-Bermudez J, Lopez-gomez M, Flores J, Arrambide G, et al. Mental disorders in Mexican patients with multiple sclerosis. J Neuropsychiatry Clin Neurosci. 2010;22:63–9.CrossRefPubMed
57.
Vattakatuchery JJ, Rickards H, Cavanna AE. Pathogenic mechanisms of depression in multiple sclerosis. J Neuropsychiatry Clin Neurosci. 2011;23:261–76.CrossRefPubMed
58.
Santoro M, Nociti V, De Fino C, Caprara A, Giordano R, Palomba N, et al. Depression in multiple sclerosis: effect of brain derived neurotrophic factor Val66Met polymorphism and disease perception. Eur J Neurol. 2016;23:630–40.CrossRefPubMed
59.
Joffe RT, Lippert GP, Gray TA, Sawa G, Horvath Z. Personal and family history of affective illness in patients with multiple sclerosis. J Affect Disord. 1987;12:63–5.CrossRefPubMed
60.
Johansson V, Lundholm C, Hillert J, Masterman T, Lichtenstein P, Landén M, et al. Multiple sclerosis and psychiatric disorders: comorbidity and sibling risk in a nationwide Swedish cohort. Mult Scler. 2014;20(14):1881–91.CrossRefPubMed
61.
Minden SL, Orav J, Reich P. Depression in multiple sclerosis. Gen Hosp Psychiatry. 1987;9:426–34.CrossRefPubMed
62.
Marrie RA. Psychiatric comorbidity in multiple sclerosis: it’s not the genes. Mult Scler. 2014;20(14):1803–5.CrossRefPubMed
63.
Schiffer RB, Weitkamp LR, Wineman NM, Guttormsen S. Multiple sclerosis and affective disorder: family history, sex and HLA-DR antigens. Arch Neurol. 1988;45:1345–8.CrossRefPubMed
64.
Julian LJ, Vella L, Frankel D, Oksenberg JR, Mohr DC. ApoE alleles, depression and positive affect in multiple sclerosis. Mult Scler. 2009;15:311–5.CrossRefPubMedCentralPubMed
65.
Gold SM, Irwin MR. Depression and immunity: inflammation and depressive symptoms in multiple sclerosis. Immunol Allergy Clin N Am. 2009;29:309–20.CrossRef
66.
Foley FW, Traugott U, LaRocca NG, Smith CR, Perlman KR, Caruso LS, et al. Psychoimmunological dysregulation in multiple sclerosis. Psychosomatics. 1988;29:398–403.CrossRefPubMed
67.
Foley FW, Traugott U, LaRocca NG, Smith CR, Perlman KR, Caruso LS, et al. A prospective study of depression and immune dysregulation in multiple sclerosis. Arch Neurol. 1992;49:238–44.CrossRefPubMed
68.
Fassbender K, Schmidt R, Mössner R, Kischka U, Kühnen J, Schwartz A, et al. Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis. Arch Neurol. 1998;55:66–72.CrossRefPubMed
69.
Kahl KG, Kruse N, Faller H, Weiss H, Rieckmann P. Expression of tumor necrosis factor and interferon mRNA in blood cells correlates with depression scores during an acute attack in patients with multiple sclerosis. Psychoneuroendocrinology. 2002;27:671–81.CrossRefPubMed
70.
Pokryszko-Dragan A, Frydecka I, Kosmaczewske A, Ciszak L, Bilinska M, Gruszka E, et al. Stimulated peripheral production of interferon-γ is related to fatigue and depression in multiple sclerosis. Clin Neurol Neurosurg. 2012;114:1153–8.CrossRefPubMed
71.
Gold SM, Kruger S, Ziegerl KJ, Krieger T, Schulz KH, Otte C, et al. Endocrine and immune substrates of depressive symptoms and fatigue in multiple sclerosis patients with comorbid major depression. J Neurol Neurosurg Psychiatry. 2011;82:814–8.CrossRefPubMed
72.
Kallaur AP, Lopes J, Oliveira SR, Simão AN, Reiche EN, de Almeida ER, et al. Immune-inflammatory and oxidative and nitrosative stress biomarkers of depression symptoms in subjects with multiple sclerosis: increased peripheral inflammation but less acute neuroinflammation. Mol Neurobiol. 2016;53:5191–202.CrossRefPubMed
73.
Berg D, Supprian T, Thomae J, Warmuth-Metz M, Horowski A, et al. Lesion pattern in patients with multiple sclerosis and depression. Mult Scler. 2000;6:156–62.CrossRefPubMed
74.
Pujol J, Bello J, Deus J, Marì-Vilalta JL, Capdevila A. Lesions in the left arcuate fasciculus region and depressive symptoms in multiple sclerosis. Neurology. 1997;49:1105–10.CrossRefPubMed
75.
Pujol J, Bello J, Deus J, Cardoner N, Marì-Vilalta JL, Capdevila A. Beck Depression Inventory factors related to demyelinating lesions of the left arcuate fasciculus region. Psychiatry Res. 2000;99:151–9.CrossRefPubMed
76.
Bakshi R, Czarnecki D, Shaikh ZA, Priore RL, Janardhan V, Kaliszky Z, et al. Brain MRI lesions and atrophy are related to depression in multiple sclerosis. NeuroReport. 2000;11:1153–8.CrossRefPubMed
77.
Feinstein A, Roy P, Lobaugh N, Feinstein K, O’Connor P, Black S. Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology. 2004;62:586–90.CrossRefPubMed
78.
Zorzon M, Zivadinov R, Nasuelli D, Ukmar M, Bratina A, Tommasi MA, et al. Depressive symptoms and MRI changes in multiple sclerosis. Eur J Neurol. 2002;9:491–6.CrossRefPubMed
79.
Kiy G, Lehmann P, Hahn HK, Eling P, Kastrup A, Hildebrandt H. Decreased hippocampal volume, indirectly measured, is associated with depressive symptoms and consolidation deficits in multiple sclerosis. Mult Scler. 2011;17:1088–97.CrossRefPubMed
80.
Gold SM, O’Connor MF, Gill R, Kern KC, Shi Y, Henry RG, et al. Detection of altered hippocampal morphology in multiple sclerosis-associated depression using automated surface mesh modeling. Hum Brain Mapp. 2014;35:30–7.CrossRefPubMed
81.
Gobbi C, Rocca MA, Riccitelli G, Pagani E, Messina R, Preziosa P, et al. Influence of the topography of brain damage on depression and fatigue in patients with multiple sclerosis. Mult Scler. 2014;20(2):192–201.CrossRefPubMed
82.
Nygard GO, Walhovd KB, Sowa P, Chepkoech JL, Bjornerud A, Due-Tonnessen P, et al. Cortical thickness and surface area relate to specific symptoms in early relapsing-remitting multiple sclerosis. Mult Scler. 2015;21(4):402–14.CrossRef
83.
Stuke H, Hanken K, Hirsch J, Klein J, Wittig F, Kastrup A, et al. Cross-sectional and longitudinal relationships between depressive symptoms and brain atrophy in MS patients. Front Hum Neurosci. 2016;10:622.CrossRefPubMedCentralPubMed
84.
Pravatà E, Rocca MA, Valsasina P, Riccitelli GC, Gobbi C, Comi G, et al. Gray matter trophism, cognitive impairment and depression in patients with multiple sclerosis. Mult Scler. 2017;23(14):1864–74.CrossRefPubMed
85.
Feinstein A, O’Connor P, Akabr N, Moradzadeh L, Scott CJ, Lobaugh NJ. Diffusion tensor imaging abnormalities in depressed multiple sclerosis patients. Mult Scler. 2010;16:189–96.CrossRefPubMed
86.
Shen Y, Bai L, Gao Y, Cui F, Tan Z, Tao Y, et al. Depressive symptoms in multiple sclerosis from an in vivo study with TBSS. Biomed Res Int. 2014;2014:148465.PubMedCentralPubMed
87.
Nigro S, Passamonti L, Riccelli R, Toschi N, Rocca F, Valentino P, et al. Structural ‘connectomic’ alterations in the limbic system of multiple sclerosis patients with major depression. Mult Scler. 2015;21(8):1003–12.CrossRefPubMed
88.
Yaldizli O, Penner IK, Yonekawa T, Naegelin Y, Kuhle J, Pardini M, et al. The association between olfactory bulb volume, cognitive dysfunction, physical disability and depression in multiple sclerosis. Eur J Neurol. 2016;23:510–9.CrossRefPubMed
89.
Zivadinov R, Zorzon M, Monti Bragadin L, Pagliaro G, Cazzato G. Olfactory loss in multiple sclerosis. J Neurol Sci. 1999;168:127–30.CrossRefPubMed
90.
Passamonti L, Cerasa A, Liguori M, Gioia MC, Valentino P, Nisticò R, et al. Neurobiological mechanisms underlying emotional processing in relapsing-remitting multiple sclerosis. Brain. 2009;132:3380–91.CrossRefPubMed
91.
Colasanti A, Guo Q, Giannetti P, Wall MB, Newbould RD, Bishop C, et al. Hippocampal neuroinflammation, functional connectivity and depressive symptoms in multiple sclerosis. Biol Psychiatry. 2016;80:62–72.CrossRefPubMedCentralPubMed
92.
Rocca MA, Pravatà E, Valsasina P, Radaelli M, Colombo B, Vacchi L, et al. Hippocampal-DMN disconnectivity in MS is related to WM lesions and depression. Hum Brain Mapp. 2015;36:5051–63.CrossRefPubMed
93.
Bonavita S, Sacco R, Esposito S, d’Ambrosio A, Della Corte M, Corbo D, et al. Default mode network changes in multiple sclerosis: a link between depression and cognitive impairment? Eur J Neurol. 2017;24:27–36.CrossRefPubMed
94.
Ysrraelit MC, Gaitán MI, Lopez AS, Correale J. Impaired hypothalamic pituitary adrenal axis activity in patients with multiple sclerosis. Neurology. 2008;71:1948–54.CrossRefPubMed
95.
Huitinga I, Erkut ZA, van Beurden D, Swaab DF. Impaired hypothalamus-pituitary-adrenal axis activity and more severe multiple sclerosis with hypothalamic lesions. Ann Neurol. 2004;55:37–45.CrossRefPubMed
96.
Zellini F, Niepel G, Tench CR, Constantinescu CS. Hypothalamic involvement assessed by T1 relaxation time in patients with relapsing-remitting multiple sclerosis. Mult Scler. 2009;15:1442–9.CrossRefPubMed
97.
Kantorová E, Poláček H, Bittšanský M, Baranovičová E, Hnilicová P, Čierny D, et al. Hypothalamic damage in multiple sclerosis correlates with disease activity, disability, depression, and fatigue. Neurol Res. 2017;39(4):323–30.CrossRefPubMed
98.
Kneebone II, Dunmore E. Attributional style and symptoms of depression in persons with multiple sclerosis. Int J Behav Med. 2004;11(2):110–5.CrossRefPubMed
99.
Ameis S, Feinstein A. Treating depressed multiple sclerosis patients. Therapy. 2007;4(3):339–47.CrossRef
100.
101.
102.
Gilchrist AC, Creed FH. Depression, cognitive impairment and social stress in multiple sclerosis. J Psychosom Res. 1994;38:193–201.CrossRefPubMed
103.
Multiple Sclerosis Society. MS insight: bridging the gap of misconceptions, MS Matters Supplement 7. London: Multiple Sclerosis Society; 1996.
104.
Miller CM. The lived experience of relapsing multiple sclerosis: a phenomenological study. J Neurosci Nurs. 1997;29(5):291–304.CrossRef
105.
Pakenham KI. Adjustment to multiple sclerosis: application of a stress and coping model. Health Psychol. 1999;18:383–92.CrossRefPubMed
106.
Lynch SG, Kroencke DC, Denney DR. The relationship between disability and depression in multiple sclerosis: the role of uncertainty, coping, and hope. Mult Scler. 2001;7(6):411–6.CrossRefPubMed
107.
Voss WD, Arnett PA, Higginson CI, Randolph JJ, Campos MD, Dyck DG. Contributing factors to depressed mood in multiple sclerosis. Arch Clin Neuropsychol. 2002;17:103–15.CrossRefPubMed
108.
Janssens ACJW, Van Doorn PA, de Boer JB, van der Meché FG, Passchier J, Hintzen RQ. Impact of recently-diagnosed multiple sclerosis on quality of life, anxiety, depression, and distress of patients and partners. Acta Neurol Scand. 2003;108:389–95.CrossRefPubMed
109.
Tsivgoulis G, Triantafyllou N, Papageorgiou C, Evangelopoulos ME, Kararizou E, Sfagos C, et al. Associations of the Expanded Disability Status Scale with anxiety and depression in multiple sclerosis outpatients. Acta Neurol Scand. 2007;115:67–72.CrossRefPubMed
110.
Solaro C, Allemani C, Messmer Uccelli M, Canevari E, Dagnino N, Pizio R, et al. The prevalence of multiple sclerosis in the north-west Italian province of Genoa. J Neurol. 2005;252(4):436–40.CrossRefPubMed
111.
Weiland TJ, Jelinek GA, Marck CH, Hadgkiss EJ, van der Meer DM, Pereira NG, et al. Clinically significant fatigue: prevalence and associated factors in an international sample of adults with multiple sclerosis. PLoS One. 2015;10(2):e0115541.CrossRefPubMedCentralPubMed
112.
Solaro C, Bergamaschi R, Rezzani C, Mueller M, Trabucco E, Bargiggia V, et al. Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study. Clin Neuropharmacol. 2013;36:114–6.CrossRefPubMed
113.
114.
Alschuler KN, Ehde DM, Jensen MP. The co-occurrence of pain and depression in adults with multiple sclerosis. Rehabil Psychol. 2013;48:217–21.CrossRef
115.
Pozzilli C, Palmisano L, Mainero C, Tomassini V, Marinelli F, Ristori G, et al. Relationship between emotional distress in caregivers and health status in persons with multiple sclerosis. Mult Scler. 2004;10:442–6.CrossRefPubMed
116.
Carletto S, Borghi M, Francone D, Scavelli F, Bertino G, Cavallo M, et al. The efficacy of a mindfulness based intervention for depressive symptoms in patients with multiple sclerosis and their caregivers: study protocol for a randomized controlled clinical trial. BMC Neurol. 2016;16:7.CrossRefPubMedCentralPubMed
117.
Patti F, Amato MP, Battaglia MA, Pitaro M, Russo P, Solaro C, et al. Caregiver quality of life in multiple sclerosis: a multicentre Italian study. Mult Scler. 2007;13(3):412–9.CrossRefPubMed
118.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983;33:1444–52.CrossRefPubMed
119.
Giordano A, Ferrari G, Radice D, Randi G, Bisanti L, Solari A. Health-related quality of life and depressive symptoms in significant others of people with multiple sclerosis: a community study. Eur J Neurol. 2012;19:847–54.CrossRefPubMed
120.
Ertekin Ö, Özakbaş S, İdiman E. Caregiver burden, quality of life and walking ability in different disability levels of multiple sclerosis. NeuroRehabilitation. 2014;34(2):313–21.PubMed
121.
Bassi M, Falautano M, Cilia S, Goretti B, Grobberio M, Pattini M, et al. The coexistence of well- and ill-being in persons with multiple sclerosis, their caregivers and health professionals. J Neurol Sci. 2014;337(1–2):67–73.CrossRefPubMed
122.
Opara J, Jaracz K, Brola W. Burden and quality of life in caregivers of persons with multiple sclerosis. Neuro Neurochir Pol. 2012;46(5):472–9.
123.
Minden SL. Psychotherapy for people with multiple sclerosis. Neuropsychiatry. 1992;4:198–213.CrossRef
124.
Barnes RH, Busse EW, Dinken H. The alleviation of emotional problems in multiple sclerosis by group therapy. Group Psychother. 1954;6:193–201.
125.
Bolding H. Psychotherapeutic aspects in the management of patients with multiple sclerosis. Dis Nerv Syst. 1960;21:24–6.PubMed
126.
Day M, Day E, Herman R. Group therapy of patients with multiple sclerosis. Arch Neurol Psychiatry. 1953;69:193–6.CrossRef
127.
Crawford JD, McIvor GP. Stress management for multiple sclerosis patients. Psychol Rep. 1987;61:423–9.CrossRefPubMed
128.
Foley FW, Bedell JR, LaRocca NG, Scheinberg LC, Reznikoff M. Efficacy of stress-inoculation training in coping with multiple sclerosis. J Consult Clin Psychol. 1987;55:919–22.CrossRefPubMed
129.
Larcombe NA, Wilson PH. An evaluation of cognitive-behaviour therapy for depression in patients with multiple sclerosis. Br J Psychiatry. 1984;145:366–71.CrossRefPubMed
130.
Mohr DC, Goodkin DE. Treatment of depression in multiple sclerosis: review and meta-analysis. Clin Psychol Sci Pract. 1999;6:1–9.CrossRef
131.
Walker ID, Gonzalez EW. Review of intervention studies on depression in persons with multiple sclerosis. Issues Ment Health Nurs. 2007;28(5):511–31.CrossRefPubMed
132.
Mohr DC, Likosky W, Bertagnolli A, Goodkin DE, Van Der Wende J, Dwyer P, et al. Telephone-administered cognitive behavioral therapy for the treatment of depressive symptoms in multiple sclerosis. J Consult Clin Psychol. 2000;68(2):356–61.CrossRefPubMed
133.
Crawford JD, McIvor GP. Group psychotherapy: benefits in multiple sclerosis. Arch Phys Med Rehabil. 1985;66:810–3.PubMed
134.
Schwartz CE. Teaching coping skills enhances quality of life more than peer support: results of a randomised trial with multiple sclerosis patients. Health Psychol. 1999;18:211–20.CrossRefPubMed
135.
Maguire B. The effects of imagery on attitudes and moods in multiple sclerosis patients. Altern Ther. 1996;2:75–9.
136.
Thomas PW, Thomas S, Hillier C, Galvin K, Baker R. Psychological interventions for multiple sclerosis. Cochrane Database Syst Rev. 2006;25;(1):CD004431.
137.
Bhattacharjee S, Goldstone L, Ip Q, Warholak T. Depression treatment among adults with multiple sclerosis and depression in ambulatory care settings in the United States. Mult Scler Int. 2017;2017:3175358.PubMedCentralPubMed
138.
Fiest KM, Walker JR, Bernstein CN, Graff LA, Zarychanski R, Abou-Setta AM, et al. Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Mult Scler Relat Disord. 2016;5:12–26.CrossRefPubMed
139.
Mohr DC, Epstein L, Luks TL, Goodkin D, Cox D, Goldberg A, et al. Brain lesion volume and neuropsychological function predict efficacy of treatment for depression in multiple sclerosis. J Consult Clin Psychol. 2003;71(6):1017–24.CrossRefPubMed
140.
Mohr DC, Classen C, Barrera M Jr. The relationship between social support, depression and treatment for depression in people with multiple sclerosis. Psychol Med. 2004;34(3):533–41.CrossRefPubMed
141.
Mohr DC, Cox D, Merluzzi N. Self-injection anxiety training: a treatment for patients unable to self-inject injectable medications. Mult Scler. 2005;11(2):182–5.CrossRefPubMed
142.
Mohr DC, Genain C. Social support as a buffer in the relationship between treatment for depression and T-cell production of interferon gamma in patients with multiple sclerosis. J Psychosom Res. 2004;57(2):155–8.CrossRefPubMed
143.
Beckner V, Vella L, Howard I, Mohr DC. Alliance in two telephone-ad- ministered treatments: relationship with depression and health outcomes. J Consult Clin Psychol. 2007;75(3):508–12.CrossRefPubMed
144.
Forman AC, Lincoln NB. Evaluation of an adjustment group for people with multiple sclerosis: a pilot randomized controlled trial. Clin Rehabil. 2010;24(3):211–21.CrossRefPubMed
145.
Baron KG, Corden M, Jin L, Mohr DC. Impact of psychotherapy on insomnia symptoms in patients with depression and multiple sclerosis. J Behav Med. 2011;34(2):92–101.CrossRefPubMed
146.
Cooper CL, Hind D, Parry GD, Isaac CL, Dimairo M, O’Cathain A, et al. Computerised cognitive behavioural therapy for the treatment of depression in people with multiple sclerosis: external pilot trial. Trials. 2011;14(12):259.CrossRef
147.
Lincoln NB, Yuill F, Holmes J, Drummond AE, Constantinescu CS, Armstrong S, et al. Evaluation of an adjustment group for people with multiple sclerosis and low mood: a randomized controlled trial. Mult Scler. 2011;17(10):1250–7.CrossRefPubMed
148.
Nordin L, Rorsman I. Cognitive behavioural therapy in multiple sclerosis: a randomized controlled pilot study of acceptance and commitment therapy. J Rehabil Med. 2011;44(1):87–90.CrossRef
149.
Bombardier CH, Ehde DM, Gibbons LE, Wadhwani R, Sullivan MD, Rosenberg DE, et al. Telephone-based physical activity counseling for major depression in people with multiple sclerosis. J Consult Clin Psychol. 2013;81(1):89–99.CrossRefPubMed
150.
Humphreys I, Drummond AE, Phillips C, Lincoln NB. Cost-effectiveness of an adjustment group for people with multiple sclerosis and low mood: a randomized trial. Clin Rehabil. 2013;27(11):963–71.CrossRefPubMed
151.
Kratz AL, Ehde DM, Bombardier CH. Affective mediators of a physical activity intervention for depression in multiple sclerosis. Rehabil Psychol. 2014;59(1):57–67.CrossRefPubMed
152.
Kiropoulos LA, Kilpatrick T, Holmes A, Threader J. A pilot randomized controlled trial of a tailored cognitive behavioural therapy based intervention for depressive symptoms in those newly diagnosed with multiple sclerosis. BMC Psychiatry. 2016;16:435.CrossRefPubMedCentralPubMed
153.
Hind D, O’Cathain A, Cooper CL, Parry GD, Isaac CL, Rose A, et al. The acceptability of computerised cognitive behavioural therapy for the treatment of depression in people with chronic physical disease: a qualitative study of people with multiple sclerosis. Psychol Health. 2010;25:699–712.CrossRefPubMed
154.
Boeschoten RE, Braamse AMJ, Aartjan Beekman TF, Cuijpers P, van Oppen P, et al. Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta-analysis. J Neurol Sci. 2017;372:331–41.CrossRefPubMed
155.
Grossman P, Kappos L, Gensicke H, D’Souza M, Mohr DC, Penner IK, Steiner C. MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology. 2010;75(13):1141–9.CrossRefPubMedCentralPubMed
156.
Çakit BD, Nacir B, Genç H, Saraçoğlu M, Karagöz A, Erdem HR, Ergün U. Cycling progressive resistance training for people with multiple sclerosis. Am J Phys Med Rehabil. 2010;89:446–57.CrossRef
157.
Dalgas U, Stenager E, Jakobsen J, Hansen HJ, Knudsen C, Overgaard K, et al. Fatigue, mood and quality of life improve in MS patients after progressive resistance training. Mult Scler. 2010;16:480–90.CrossRefPubMed
158.
Dettmers C, Sulzmann M, Ruchay-Plössi A, Ruchay-Plössl A, Gütler R, Vieten M. Endurance exercise improves walking distance in MS patients with fatigue. Acta Neurol Scand. 2009;120:251–7.CrossRefPubMed
159.
Hebert JR, Corboy JR, Manago MM, Schenkman M. Effects of vestibular rehabilitation on multiple sclerosis-related fatigue and upright postural control: a randomized controlled trial. Phys Ther. 2011;91:1166–83.CrossRefPubMed
160.
Learmonth YC, Paul L, Miller L, Mattison P, McFadyen AK. The effects of a 12-week leisure centre-based, group exercise intervention for people moderately affected with multiple sclerosis: a randomized controlled pilot study. Clin Rehabil. 2011;26:579–93.CrossRefPubMed
161.
Oken BS, Kishiyama S, Zajdel Bourdette D, Carlsen J, Haas M, et al. Randomized controlled trial of yoga and exercise in multiple sclerosis. Neurology. 2004;62:2058–64.CrossRefPubMed
162.
Petajan JH, Gappmaier E, White AT, Spencer MK, Mino L, Hicks RW. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol. 1996;39:432–41.CrossRefPubMed
163.
Romberg A, Virtanen A, Ruutiainen J. Long-term exercise improves functional impairment but not quality of life in multiple sclerosis. J Neurol. 2005;252:839–45.CrossRefPubMed
164.
Roppolo M, Mulasso A, Gollin M, Bertolotto A, Ciairano S. The role of fatigue in the associations between exercise and psychological health in multiple sclerosis: direct and indirect effects. Ment Heal Phys Act. 2013;6:87–94.CrossRef
165.
Schulz KH, Gold SM, Witte J, Bartsch K, Lang UE, Hellweg R, et al. Impact of aerobic training on immune-endocrine parameters, neurotrophic factors, quality of life and coordinative function in multiple sclerosis. J Neurol Sci. 2004;225:11–8.CrossRefPubMed
166.
Sutherland G, Andersen MB, Stoové MA. Can aerobic exercise training affect health-related quality of life for people with multiple sclerosis? J Sport Exerc Psychol. 2001;23:122–35.CrossRef
167.
Burschka JM, Keune PM, Hofstadt-van Oy U, Oschmann P, Kuh P. Mindfulness-based interventions in multiple sclerosis: beneficial effects of Tai Chi on balance, coordination, fatigue and depression. BMC Neurol. 2014;4:165.CrossRef
168.
Choobforoushzadeh A, Neshat-Doost HT, Molavi H, Abedi MR. Effect of Neurofeedback training on depression and fatigue in patients with multiple sclerosis. Appl Psychophysiol Biofeedback. 2015;40(1):1–8.CrossRefPubMed
169.
170.
Lefaucher JP, Andrè-Obadia N, Antal A, Baeken C, Benninger DH, Cantello RM, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol. 2014;125(11):2150–6.CrossRef
171.
Mondino M, Bennabi D, Poulet E, Galvao F, Brunelin J, Haffen E. Can transcranial direct current stimulation (tDCS) alleviate symptoms and improve cognition in psychiatric disorders? World J Biol Psychiatry. 2014;15:261–75.CrossRefPubMed
172.
Shiozawa P, Fregni F, Bensenor IM, Lotufo PA, Berlim MT, Daskalakis JZ, et al. Transcranial direct current stimulation for major depression: an updated systematic review and meta-analysis. Int J Neuropsychopharmacol. 2014;17(9):1443–52.CrossRefPubMed
173.
Koch G, Rossi S, Prosperetti C, Codecà C, Monteleone F, Petrosini L, et al. Improvement of hand dexterity following motor cortex rTMS in multiple sclerosis patients with cerebellar impairment. Mult Scler. 2008;14(7):995–8.CrossRefPubMed
174.
Centonze D, Koch G, Versace V, Mori F, Rossi S, Brusa L, et al. Repertitive transcranial magnetic stimulation of the motor cortex ameliorates spasticity in multiple sclerosis. Neurology. 2007;68:1045–50.CrossRefPubMed
175.
Centonze D, Petta F, Versace V, Rossi S, Torelli F, Prosperetti C, et al. Effects of motor cortex rTMS on lower urinary tract dysfunction in multiple sclerosis. Mult Scler. 2007;13:269–71.CrossRefPubMed
176.
Mori F, Codecà C, Kusayanagi H, Monteleone F, Boffa L, Rimano A, et al. Effects of intermittent theta burst stimulation on spasticity in patients with multiple sclerosis. Eur J Neurol. 2010;17:295–300.CrossRefPubMed
177.
Mori F, Ljoka C, Magni E, Kusayanagi H, Monteleone F, Sancesario A, et al. Transcranial magnetic stimulation primes the effects of exercise therapy in multiple sclerosis. J Neurol. 2011;258:1281–7.CrossRefPubMed
178.
Hind D, Cotter J, Thake A, Bradburn M, Cooper C, Isaac C, House A. Cognitive behavioural therapy for the treatment of depression in people with multiple sclerosis: a systematic review and meta-analysis. BMC Psychiatry. 2014;14(1):5.CrossRefPubMedCentralPubMed
179.
Mohr DC, Hart SL, Fonareva I, Tasch ES. Treatment of depression for patients with multiple sclerosis in neurology clinics. Mult Scler. 2006;12:204–8.CrossRefPubMed
180.
Cetin K, Johnson KL, Ehde DM, Kuehn CM, Amtmann D, Kraft GH. Antidepressant use in multiple sclerosis: epidemiologic study of a large community sample. Mult Scler. 2007;13:1046–53.CrossRefPubMed
181.
Koch MW, Glazenborg A, Uyttenboogaart M, Mostert J, De Keyser J. Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database Syst Rev. 2011;(2):CD007295.
182.
Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry. 1990;147:1493–7.CrossRefPubMed
183.
Ehde DM, Kraft GH, Chwastiak L, Sullivan MD, Gibbons LE, Bombardier CH, et al. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. Gen Hosp Psychiatry. 2008;30:40–8.CrossRefPubMed
184.
185.
Dean G. A double-blind trial with an antidepressant drug, imipramine, in multiple sclerosis. S Afr Med J. 1969;43:86–7.PubMed
186.
Scott TF, Nussbaum P, McConnell H, Brill P. Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carroll scale. Neurol Res. 1995;17:421–2.PubMed
187.
Barak Y, Ur E, Achiron A. Meclobemide treatment in multiple sclerosis patients with comorbid depression: an open-label safety trial. J Neuropsychiatry Clin Neurosci. 1999;11:271–3.CrossRefPubMed
188.
Shafey H. The effect of fluoxetine in depression associated with multiple sclerosis. Can J Psychiatry. 1992;37:147–8.CrossRefPubMed
189.
Julian LJ, Mohr DC. Cognitive predictors of response to treatment for depression in multiple sclerosis. J Neuropsychiatry Clin Neurosci. 2006;18:356–63.CrossRefPubMed
190.
Lana-Peixoto MA, Teixeira AL Jr, Haase VG. Interferon beta 1A induced depression and suicidal ideation in multiple sclerosis. Arq Neuropsiquiatr. 2002;60(3-B):721–4.
191.
Feinstein A. An examination of suicidal intent in patients with multiple sclerosis. Neurology. 2002;59(5):674–8.CrossRefPubMed
192.
Zephir H, De Seze J, Stojkovic T, Delisse B, Ferriby D, Cabaret M, et al. Multiple sclerosis and depression: influence of interferon beta therapy. Mult Scler. 2003;9(3):284–8.CrossRefPubMed
193.
Patten SB, Francis G, Metz LM, Lopez-Bresnahan M, Chang P, Curtin F. The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Mult Scler. 2005;1(2):175–81.CrossRef
194.
PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139):1498–504.
195.
Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1A therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 2000;343(13):898–904.CrossRefPubMed
196.
The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):655–61.CrossRef
197.
Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse-remitting rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Group. Neurology. 1995;45:1268–76.CrossRefPubMed
198.
O’Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, TEMSO Trial Group, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293–303.CrossRefPubMed
199.
Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, DEFINE Study Investigators, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098–107.CrossRefPubMed
200.
Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, FREEDOMS Study Group, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401.CrossRefPubMed
201.
Hunter SF, Agius M, Miller DM, Cutter G, Barbato L, McCague K, et al. Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: an analysis from the EPOC (Evaluate Patient OutComes) trial. J Neurol Sci. 2016;15(365):190–8.CrossRef
202.
Penner IK, Sivertsdotter EC, Celius EG, Fuchs S, Schreiber K, Berkö S, et al. Improvement in fatigue during Natalizumab treatment is linked to improvement in depression and day-time sleepiness. Front Neurol. 2015;6:18.CrossRefPubMedCentralPubMed
203.
Williams RM, Turner AP, Hatzakis M Jr, Bowen JD, Rodriquez AA, Haselkorn JK. Prevalence and correlates of depression among veterans with multiple sclerosis. Neurology. 2005;64(1):75–80.
204.
Sollom AC, Kneebone II. Treatment of depression in people who have multiple sclerosis. Mult Scler. 2007;13(5):632–5.CrossRefPubMed
205.
Beiske AG, Svensson E, Sandanger I, Czujko B, Pedersen ED, Aarseth JH, et al. Depression and anxiety amongst multiple sclerosis patients. Eur J Neurol. 2008;15(3):239–45.CrossRefPubMed
206.
Patten SB, Berzins S, Metz LM. Challenges in screening for depression in multiple sclerosis. Mult Scler. 2010;16(11):1406–11.CrossRefPubMed
207.
Mattioli F, Bellomi F, Stampatori C, Parrinello G, Capra R. Depression, disability and cognitive impairment in multiple sclerosis: a cross sectional Italian study. Neurol Sci. 2011;32(5):825–32.CrossRefPubMed
208.
Honer WG, Hurwitz T, Li DKB, Palmer M, Paty DW. Temporal lobe involvement in multiple sclerosis patients with psychiatric disorders. Arch Neurol. 1987;44:187–90.CrossRefPubMed
209.
Reischies FM, Baum K, Brau H, Hedde JP, Schwindt G. Cerebral magnetic resonance imaging findings in multiple sclerosis. Arch Neurol. 1988;45:1114–6.CrossRefPubMed
Metadaten
Titel
Depression in Multiple Sclerosis: Epidemiology, Aetiology, Diagnosis and Treatment
verfasst von
Claudio Solaro
Giulia Gamberini
Fabio Giuseppe Masuccio
Publikationsdatum
01.02.2018
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 2/2018
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-018-0489-5

Weitere Artikel der Ausgabe 2/2018

CNS Drugs 2/2018 Zur Ausgabe

Review Article

Use of α2δ Ligands for Restless Legs Syndrome/Willis Ekbom Disease

Editorial

Botulinum Toxin: Does it have a Place in the Management of Depression?

Review Article

An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis

Systematic Review

Prescribed Dose of Opioids and Overdose: A Systematic Review and Meta-Analysis of Unintentional Prescription Opioid Overdose

Original Research Article

Effect of the Glutamate NMDA Receptor Antagonist Memantine as Adjunctive Treatment in Borderline Personality Disorder: An Exploratory, Randomised, Double-Blind, Placebo-Controlled Trial

Review Article

Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 | Parkinson-Krankheit | Podcast | Nachrichten

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus
Professorin Dr. Claudia Trenkwalder, Neurologin

22.04.2024 | DGIM 2024 | Nachrichten

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

19.04.2024 | AAN-Jahrestagung 2024 | Nachrichten

Hustenstiller lindert Agitation bei Alzheimer
weitere anzeigen

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise